A PHASE 2B PLACEBO-CONTROLLED, RANDOMIZED STUDY OF A RESPIRATORY SYNCYTIAL VIRUS (RSV) VACCINE IN PREGNANT WOMEN

Completed · Phase 2 · Has a placebo group

Conditions studied: Respiratory Tract Infection

In brief

This Phase 2b study will evaluate the safety, tolerability, and immunogenicity of an RSV vaccine in pregnant participants who receive either one of 2 dose levels of the vaccine, formulated with or without aluminum hydroxide, or placebo, and investigate safety and characteristics of antibodies in their infants.

Key facts

Study ID
NCT04032093
Run by
Pfizer
People needed
1153
Starts
2019-08-07
Expected to finish
2021-09-30
Last updated by the study team
2022-10-18

Who can join

Age: 18 and older, up to 49. Sex: female. Healthy volunteers: accepted.

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.